NRx Pharmaceuticals, Inc.
NRXP
$3.37
-$0.10-2.88%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 6.03% | 74.06% | 103.97% | -262.91% | -122.62% |
| Total Depreciation and Amortization | 17,400.00% | 16,400.00% | 9,900.00% | 2,050.00% | -200.00% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -100.00% | -- |
| Total Other Non-Cash Items | -22.40% | -299.94% | -182.68% | 291.27% | 515.17% |
| Change in Net Operating Assets | -567.64% | -- | 1,679.07% | 1,218.60% | -116.93% |
| Cash from Operations | -120.33% | -23.42% | -76.98% | -25.37% | -57.22% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -91.53% | -- | -100.00% | -107.65% | -- |
| Total Debt Repaid | 32.43% | -- | 95.92% | 100.00% | -7,300.00% |
| Issuance of Common Stock | -- | -- | -- | 2,736.99% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 730.43% | 1,078.29% | 208.68% | 143.04% | -- |
| Cash from Financing | 2,024.60% | -54.86% | 141.42% | 373.52% | -55.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 857.13% | -126.41% | 401.97% | 1,796.03% | -555.61% |